← Russell 3000 cross-section

STRO SUTRO BIOPHARMA, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$357m
Revenue TTM
$46m
Net income TTM
$-181m
Free cash flow
Composite score
Sector rank
#2572

Valuation

P / E
EV / EBITDA
EV / sales
4.2
FCF yield
Earnings yield vs 10-yr
-55.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-395.2%
EBITDA margin
-306.3%
ROE
174.8%
ROIC
Revenue growth
-56.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In June 2023, we entered into a purchase and sale agreement, or the Purchase Agreement with Blackstone, in which Blackstone acquired the right to receive our 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte products, including Vaxcyte’s pneumococcal conjugate vaccine, or PCV, products, such as VAX-24 and VAX-31. Following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of an amendment to the licensing agreement, the revenue interest in the 4% royalty on potential future sales of Vaxcyte products other than Vaxcyte’s PCV products reverted to us. …SUTRO BIOPHARMA, INC., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →